Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Common Equity (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Common Equity for 11 consecutive years, with $44.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 220.79% to $44.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.2 million through Dec 2025, up 220.79% year-over-year, with the annual reading at $44.2 million for FY2025, 220.79% up from the prior year.
  • Common Equity hit $44.2 million in Q4 2025 for Seres Therapeutics, up from $43.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $175.7 million in Q3 2021 to a low of -$87.1 million in Q2 2024.
  • Historically, Common Equity has averaged $35.6 million across 5 years, with a median of $28.4 million in 2024.
  • Biggest five-year swings in Common Equity: soared 333.1% in 2021 and later tumbled 515.99% in 2023.
  • Year by year, Common Equity stood at $131.5 million in 2021, then plummeted by 91.8% to $10.8 million in 2022, then crashed by 515.99% to -$44.9 million in 2023, then surged by 130.73% to $13.8 million in 2024, then skyrocketed by 220.79% to $44.2 million in 2025.
  • Business Quant data shows Common Equity for MCRB at $44.2 million in Q4 2025, $43.7 million in Q3 2025, and $32.9 million in Q2 2025.